Bloomington woman talks about the other side of the opioid epidemic

One in 10 Opioid Users Treated With Naloxone Die

https://www.medscape.com/viewarticle/887848

WASHINGTON, DC — About 10% of people who overdose on opioids and are treated with naloxone die within a year, new research shows.

The reason for the study was to get a concrete statistic to share with people who overdose that would spur them to get help for their addiction, which the “vast majority” don’t seek, said investigator Scott Weiner, MD, director of the comprehensive opioid response and education program at Brigham and Women’s Hospital in Boston.

“Now I tell patients that you have a one in 10 chance you will be dead within a year,” he told Medscape Medical News. “I want it to hit home. I want them to understand the scope of the problem.”

Dr Weiner and his colleagues tracked more than 12,000 naloxone administrations in Massachusetts over 30 months, which averages out to about 406 each month.

 

Of the people who received the opioid overdose antidote from emergency medical services personnel, 6.5% died the same day, Dr Weiner reported here at the American College of Emergency Physicians (ACEP) 2017 Scientific Assembly.

Just under 10% of people who received naloxone died within a year, and half of those died within a month.

And of those who died within a year, about 40% died outside a hospital.

“That, to me, means that people are dying before healthcare can get to them,” Dr Weiner explained. These are the people who using opioids at home, by themselves, and are found dead. “That’s where bystander naloxone needs to come into play. If friends and family know someone is using, they need to have naloxone.”

Congress is considering legislation that would allow naloxone to be sold over the counter, which makes sense because naloxone “is a much safer medication than Tylenol,” he pointed out. Currently, the loved ones of opioid users can obtain it through a physician’s standing order, but “it’s still a little circuitous.”

People who abuse opioids should be considered to be at extremely high risk, and should receive interventions — such as buprenorphine, counseling, and referral to treatment — before they are discharged from the hospital, he added.

A related study presented at the meeting indicates that more than half the patients who present to the emergency department with opioid misuse problems suffer from mental health issues and high rates of early childhood trauma exposure.

Results from a recent ACEP poll of 1261 emergency physicians suggest that the number of patients seeking opioids in emergency departments has increased or remained the same in the past year.

 

Virtually every emergency physician in the country is affected by the opioid crisis, said ACEP President Paul Kivela, MD, from the Napa Valley Emergency Medical Group in California, who presented the poll results.

 

According to 57% of respondents, detox and rehabilitation facilities are rarely or never accessible, which leads to few referral options.

 

“It’s been a problem for a long time, and the majority of emergency physicians out there say there are no treatment programs for these patients,” said Dr Kivela. “We need to expand our capabilities or scope of care.”

 

He said he is pleased that President Trump has declared the opioid crisis a public health emergency, and hopes the federal government will provide financial and other resources to help tackle the epidemic.

It’s heartbreaking and shameful that people who genuinely want help can’t get it.
 

The study findings and poll results are “extremely relevant” to what emergency physicians experience every day, said Angela Mattke, MD, from US Acute Care Solutions in Cleveland.

 

Several years ago, she handled about one opioid overdose each month, she told Medscape Medical News. “Now I see several a shift.”

 

“Because naloxone is now so widely available, I’m seeing fewer overdoses,” she added. “Frequently, I do have patients who would like addiction treatment, but there are no resources available. It’s heartbreaking and shameful that people who genuinely want help can’t get it.”

 

Dr Weiner is a shareholder and member of the scientific advisory board for General Emergency Supplies and Epidemic Solutions. Dr Kivela and Dr Mattke have disclosed no relevant financial relationships.

 

American College of Emergency Physicians (ACEP) 2017 Scientific Assembly: Abstract 402. Presented October 30, 2017.

 

Follow Medscape on Twitter @Medscape and Maureen Salamon @maureensalamon

 
 

Med non-compliance crisis :About 125,000 people die annually because they took their medications incorrectly ?

Patients Forgetting Medication Can Be Costly, Fatal. Is Tech The Answer?

http://www.capradio.org/articles/2018/01/04/patients-forgetting-medication-can-be-costly-fatal-is-tech-the-answer/

Neil W. MacLean and Sue Carey have built a quiet, simple life in their Sacramento home. The sitting room is lined with books, the coffee table covered in magazines and newspapers. Their long-haired dachshund Wally dozes to the ticking of a grandfather clock.

MacLean is 83, and he’s been cautiously optimistic since receiving an Alzheimer’s diagnosis two years ago. He’s in the early stages, and he can still mostly keep track of his medications — with a little help from Carey.

Every Sunday, Carey sorts MacLean’s five prescriptions and assorted vitamin supplements into a pill organizer. He takes the pills and writes down what he took. Carey double checks to make sure he swallowed everything.

Sometimes, though, MacLean forgets to log the pills.

“If I’m not sure if I’ve taken it, we just skip it,” he said. “Because we figure that’s safer than doubling up.”

010318Pills (P)Neil W. Maclean and his partner, Sue Carey, keep track of his medication in a box marked with the days of the week. (Andrew Nixon / Capital Public Radio)

It’s the sort of patient error that doctors and pharmacists are worried about. About 125,000 people die annually because they took their medications incorrectly, and the problem costs the healthcare system more than $100 billion a year, according to an analysis from health research institute IQVIA.

Dr. Dean Schillinger, a primary care doctor at Zuckerberg San Francisco General Hospital and a professor of medicine at UC San Francisco, said there are a lot of reasons behind what experts call “medication nonadherence.” Some patients feel the cost of their medication is too high, or they don’t understand why they have to take it. Others have trouble reading the labels or doing the math on dosage.

He said there’s often a breakdown in communication between doctors and patients, or patients and pharmacists.

“We talk about a lot of errors that are done in hospitals, but we don’t talk a lot about errors that we, common folk, make at home,” he said. “The issue of adherence is one of the most complex human behaviors that one could study.”

Technology is rapidly emerging as a possible solution. At least 50 health care companies focused exclusively on helping people take their medications have popped up in the last few years — six of them in California, according to startup site AngelList.

Some pharmacies recently started selling prescription vials with countdowns on the cap that tell patients how long it’s been since they last popped the top. The vial can also send email or text reminders and create medication reports.

This fall, the U.S. Food and Drug Administration made headlines for approving the first “digital pill.” The medication, intended for schizophrenia, is embedded with a special sensor connected to a patch on the stomach. When the pill hits the stomach, a patch the patch alerts a mobile app that the dose was ingested.

These innovations tend to be expensive, and they’re not well known to the average patient. But Dan Gebremedhin, a principal at a healthcare-focused venture capital firm in Boston, said he expects they’ll have a growing presence on the market.

“You’re just going to see more of it. It’s not going to slow down, it’s only going to speed up.”

BJRX Pharmacy in Stockton is trying something new to help patients stick to their medications. This fall, they installed a pill-dispensing robot from a company called Omnicell. It looks a bit like a vending machine.

A pharmacy employee can feed a patient’s prescription regimen into the machine, and the machine produces a day-by-day packet with up to four dose times for each day. The machine sorts through all the patient’s medications and distributes exactly what’s needed into each of the packet’s dose compartments. The compartments are tear-off, so patients can travel with a week’s worth of doses or even just a few hours.

Jeannie Duckworth, regional long-term care sales director for the pharmacy, said the packets get delivered to patients at 150 facilities across California who would otherwise be manually counting out pills from vials into organizers, also called “med minders.”

“They’re using good old pill bottles, and it’s very confusing,” she said. “It’s a lot of work. And a lot of times the med minders themselves don’t have the right amount of slots. So, we’ve taken care of morning, noon, evening and night for them.”

Schillinger of UCSF said there are other innovations that could be implemented on the pharmacy level, such as standardized, easy-to-read labels for prescription bottles and more accommodation for people who don’t read English.

But he said the lack of collaboration between pharmacies, hospitals and physicians has historically hindered efforts to improve medication adherence on a large scale.

“It’s a fragmented health system, and no one entity has the incentive to do this — to invest the funds needed to create a logical system on this,” he said. “So, what you get is chaos.”

Neil MacLean said that, if he eventually can’t remember to take his medications on his own, he’ll rely more heavily on his partner, Sue Carey, to guide him. He’s still in the early stages of the disease, so he can do a lot for himself.

He said he still remembers most of his career as an architect, his childhood in Brooklyn and the last 40 years with Carey. He also remembers what happened to his father — also a victim of the degenerative brain disease that slowly chips away at cognitive function.

“He didn’t even know his own name toward the end,” he said. “I remember at the time thinking, ‘Geez, I hope that doesn’t happen to me.’ …  Well, it’s happening.”

The Alzheimer’s Association has a tip sheet on taking medications. They also give free advice through the Alzheimer’s Association 24-seven helpline at (800) 272-3900.
people who abuse opiates and other controlled substances are typically TAKING MORE THAN THEY ARE PRESCRIBED… which is basically a NON-COMPLIANCE ISSUE… Prescribers are held responsible for people taking more than they are prescribed and occasionally dies of a OD… but.. no one is being held responsible for pts NOT TAKING THEIR MEDICATIONS.
Pharmacy/Pharmacists could be at the forefront of this… they know the last time that a pt got a prescription filled and the number of doses they are suppose to take every day…
With reportedly 125,000 people dying every year because people don’t take their medications as prescribed… are we headed toward a point where some of the healthcare professionals going to be held responsible for their failure ?
IF not, then why are we holding physicians responsible for pts taking more than prescribed and ODing ?

CVS/Aetna merger: becoming a healthcare provider with an economic orientation to care outside of hospitals

Healthcare at the tipping point: 2018 has high risks for hospitals

http://www.philly.com/philly/health/health-cents/healthcare-at-the-tipping-point-2018-has-high-risks-for-hospitals-20180104.html

Innovation has been a buzz word and marketing tagline in healthcare for more than a decade.  Virtually every organization has invested in staffing an innovation activity.  Despite these investments the pace of change has been frustrated by an entrenched reliance of providers on traditional ways that they make money.  Healthcare organizations remain disproportionately dependent upon high utilization rates of expensive inpatient services.

 Certainly, there have been changes in healthcare.  There has been an enormous amount of consolidation and attempts to improve economies of scale. 

There has been a constant effort to aggregate physicians, align them with hospital providers and organize care more economically across the inpatient and outpatient settings.

Nonetheless change has been painfully slow.  Two recent transactions, Optumcare’s acquisition of DaVita Medical Group and CVS’s acquisition of Aetna herald that change will rapidly accelerate in the near future, threatening those that rely on historic business models.  The tipping point is here.

The common denominator of the CVS and Optumcare transactions is the focus on the provision of care outside of hospitals coupled with creative strategies to manage financial risk for populations. 

Both CVS and Optumcare have insurance capabilities and data to manage excess utilization.  The CVS and Optumcare strategies are aimed at producing enormous profits by moving care from high cost fee-for-service competitors.

  CVS’s acquisition includes Aetna’s “transformative markets initiative” which is focused not on expanding its insurance base (United), but rather becoming a healthcare provider with an economic orientation to care outside of hospitals.  Optumcare’s war chest to acquire physician practices in key markets combined with the analytics of its sister organization, Optum Analytics, places them in a position of materially disrupt markets and drive down costs.

The basis for the economic battle is clear.  The table below represents the stratification of the highest components of cost in healthcare:

Total national healthcare expenditures $3.2 Trillion
$1.04 Trillion Hospital costs
$.84Trillion physician and professional services
$.43 Trillion pharma and retail medical products
$.21 Trillion private health insurance expenditures
 

Both CVS and Optumcare have direct control over all the factors listed above except for hospital cost.  Their intent is clear.  They will move as large a portion as possible of the $1.04 Trillion spent on hospitals to less expensive care outside of the hospital environment. They are incented to invest in easier and more convenient ways to meet patient needs.  They will be early adapters of new technology, expanded roles for nurses and physician assistants, and care in the home.

What is the risk for hospitals now that we are at this tipping point?  Though inpatient care is a critical part of healthcare services, the demand for hospital admissions will dramatically decline resulting in less financially sound hospitals with increasingly burdensome overhead costs.  Because a majority of capital available to healthcare has been invested in inpatient facilities, many hospitals will lack the capital to transform and directly compete with disruptive organizations like CVS and Optumcare.  The fundamental question to be faced by hospital leadership is “can we move at a sufficient pace to counter the predictable changes which will come from the disruption of these new and well-funded competitors”?

Unfortunately, historical evidence suggests that many hospitals will continue to embrace traditional economics of their current business models.  Many will dismiss the implications of this critical junction, this “tipping point”, until they find themselves in highly compromised economic circumstances.  This tipping point will result in the sudden and dramatic economic decline of many hospitals which now are seen as stable and strong organizations in our communities.

Counting on the national pharmacy chains to “take care of you” ?

My husband and I have been refuses our medication because the pharmacy says they only get a certain amount. And it is not a neighborhood doctor that they are familiar with. My husband and I have both been on these prescriptions for pain control and is been on them for a little while now, well on it long enough that not getting on medication may end up sending us to an emergency room that I have a feeling Will not give us medication that even for a few days. My doctor called the pharmacist in my neighborhood they called Walmart because there a national chain. My doctor has even called medications in  Hawaii. He tried to get our prescriptions called in and they refused him he is has federal number, they have the medication in pharmacies in the neighborhood. And there’s a blizzard going on in from here in Pennsylvania where we are right now up the eastern seaboard we were going to leave today to go into New York, to see a doctor, actually more than one doctor. Family and due to the snow we cannot drive in there today the prescription I am speaking about is the suboxone which has to be already by computer, I have my prescription from last month that I could show them that it’s a legitimate doctor they can also call the Pharmacy guy usually using New York to find out they’ve been Fiskett prescribing it for years and they refused to do any of that my Dr. even went as far as calling Walmarts corporate office. He had no success they don’t know the doctor so therefore they will fill it but when you punch mine on my husbands name in the national computer it comes up what medications were on so we’re not Dr. hunting we’re not drug seeking these are medications that are prescribed for conditions that we have it’s legal I have last months empty prescription on me and it comes out if you put it in the computer because since come up when we’ve gone to dock is not for that medication but any doctor for any reason these look up to see what medications you’re taking so the choices to drive to New York in a blizzard, or to go without a medication which ended by 24 hours if I don’t have my next dose medication can put me into such stress on my body that I could have a stroke and seizures. We only found out that this phone was going to be this Ed left last evening so there was no time to make arrangements to come in earlier in the week. Plus my doctor was on a little bit of a vacation so he wasn’t taking patients until the fourth and fifth they had covering PAs and I was good until today with my medication and he came back yesterday. Because of disabilities the doctor is really concerned with us driving to New York to try to get on medications today Anna you’re now there are several doctors we keep in New York I has been is Disabled’s, so we keep a few doctors in New York not just this one he personally called and spoke to the pharmacist to assure her that this is it legitimate danger for us not to have a medication and or to drive to New York today. Very upset and so are we. So she is causing our bodies harm may even end up in emergency room. And they might not even be able to give us that the emergency room don’t know if they carry it . Snow is falling at 2 inches an hour with 8 inches on the ground already go to where we have to go. And my mother-in-law or who’s house were staying out when we go see the doctors and my granddaughter. Is 80 years old I cannot send her out in this whether to grab my prescriptions today from the pharmacy is my doctor was to call it in in New York I would still have no way of getting it is you have two out inches an hour there’s a blizzard going on visibility is a quarter-mile. Bottom line I need my medication I have a legal prescription and illegal doctor prescribing it who has a federal number to prescribe this medication they all have Suboxone in their pharmacies in my area but I’m not one of the regular customers they won’t even give me a 2 to 3 day supply till I can go see my doctors they’re putting my bought body and my husband’s body in danger of seizures and everything else there’s no reason for them to deny this we had the open computer system they can look into it see that the same has-beens prescribing the same medication for years they can Google him if they want and find out that he’s a very good legitimate Dr. thank you for listening hopefully you can help us with this and rectify this situation there’s power outages everywhere on top by the way my name is D M telephone number xxx.xxx.xxxx thank you in advance for your help myself phone number is xxx.xxx.xxxx thank you, by the way we’re both in our 50s were not young kids that they need to be concerned about.

The DEA has stated that pts that travel a long distant to see a prescriber or to get a prescription filled is a RED FLAG and apparently in some pharmacist’s minds…there is no extenuating circumstances that they could determine that what appears to be a RED FLAG is really an anomaly and the life’s road that everyone travels from time to time should be perfectly smooth.

The rest of us, who live in the “real world”, understand that there are no “perfect circles” in our lives and especially when mother nature gets involved.

Once again here is a website that can help anyone find a independent pharmacy by Zip Code http://www.ncpanet.org/home/find-your-local-pharmacy

Having had my own independent pharmacy for 20 yrs, I understand the mindset and they are less likely to “play games” with pt’s legit medical needs and will go “above and beyond” to see that pts are taken care of.

It is a shame that pts are going to be forced to schedule vacations and other trips around their prescription refill dates… because many pharmacists will not let you refill a prescription early because of travel plans.

Nevada: new opiate law will provide further disincentives to take care of chronic-care patients

Sacrificing Pain Patients to Stop Opioid Epidemic?

 http://www.nationalreview.com/corner/455136/sacrificing-pain-patients-stop-opioid-epidemic

I’m all for fighting the opioid epidemic. But not at the price of preventing patients from receiving quality medical care. And that may be happening. Nevada doctors are apparently up in arms at a new Nevada law that they say is so vague, it could chill their proper prescribing practices. From the Las Vegas Review Journal story: It’s been only three days since Nevada’s new opioid prescription law took effect, and doctors already are venting about its impact on their practices. About 40 physicians, lawyers and others attended a meeting of the state medical and dental boards Wednesday in Las Vegas to express concerns over draft disciplinary rules for doctors who issue illegal, fraudulent, unauthorized or “otherwise inappropriate” prescriptions for pain medications under the law. Several doctors said the law makes unreasonable paperwork demands, while the proposed regulations don’t specify the types of conduct that could lead to penalties or even the loss of their medical licenses. More: But doctors who attended the meeting complained that the proposed regulations don’t specify what constitutes a violation and expressed concerns that they could be penalized for relatively minor infractions, such as forgetting to pull up a patient’s prescription history, or that an employee could make a mistake. Doctors also are worried that the threat of discipline will funnel patients from specialists to primary care physicians to pain management clinics, which say they already are inundated. Dan Laird, a pain management specialist at Flamingo Pain Specialists and a Las Vegas attorney, said in an interview with the Review-Journal that he has a stack of referrals from primary care doctors received over the past two days sitting on his fax machine. “

It will provide further disincentives to take care of chronic-care patients

” Laird said. I am weary of how we punish the law-abiding and productive sectors of our society in order to protect people who may have serious addictions or criminal intentions. I mean, that’s why we have to limit our Sudafed purchases to once a month and present our driver’s licenses to get a non-prescription medication. That’s a small inconvenience. But if you are in real pain and have to jump through continual bureaucratic hoops just to obtain proper medicine–or if you are an MD afraid to properly treat your patients–protecting those who abuse these drugs from themselves comes at a very high cost.

 

Prescribing opioids – Navigating the minefields

Image result for graphic walking thru a mine fieldMaking healthcare safe for doctors

file:///C:/Users/steve/AppData/Local/Packages/microsoft.windowscommunicationsapps_8wekyb3d8bbwe/LocalState/Files/S0/9796/Medical%20Malpractice%20Insurance%20is%20Not%20Enough%20%E2%80%93%20Medical%20JusticePrescribing%20opioids%20%E2%80%93%20Navigating%20the%20minefields[10789].htm

Treating patients in pain with opioids creates serious legal quandaries for doctors.

A 2010 study (based on the American Society of Anesthesiologists Closed Claims Database) found that malpractice claims related to chronic non-cancer pain management primarily involved patients with a history of risk behaviors.

The study also found that death was the most common trigger of these claims.

Prescribing opioids causes a conflict. No doctor wants to undertreat the patient in pain. No doctor one wants the excess liability created by patients who are addicts, criminals, or a complex mishmash of unrelenting pain issues and co-morbidities.

On the other hand, that study also found that 59% of claims were grounded in physician mismanagement, either on its own or compounding a patient risk factor.

 

This means doctors still control the legal destiny of these cases. Steps can be taken to reduce the physician’s risk of being prosecuted as a “pill mill” or being held responsible for the dangerous or felonious use of the medication by the patient.

I. General principles and practices to avoid liability

 

The framework comes from the guidelines in the 2013 Federation of State Medical Boards Model Policy On The Use Of Opioid Analgesics In The Treatment Of Chronic Pain.

 

To avoid problems, think like your state board.

 

The Model Policy makes defines a stance an investigator will take to parse the issues. Chronic pain is acknowledged as a serious public health issue. Persistent pain is acknowledged as an indicator of under-treatment. Those preamble statements are then quickly followed by the statement that some pain just does not go away. The real focus will be on excessive and inappropriate treatment.

 

The Model Policy then segues into looking to physicians for their role in abuse, misuse and diversion of these drugs.

 

Persistent pain, in it of itself, will not be an adequate defense to a charge of over-prescribing.

 

The Model Policy then goes on to actually list pitfalls that lead to excessive prescribing, telling physicians what specific elements in their own practice they need to shore up to avoid running afoul of an official investigation.

 

These are:

 

  • Lack of knowledge as to “best practices.”
  • Inadequate research into the cause of the pain and treatments for it.
  • Not understanding the causes and manifestations of addiction.

Actions more likely to manifest into a disciplinary situation are resorting too quickly too opioids and not monitoring for dependence.

The Model Policy then notes that state medical boards will consider the following to be inappropriate management:

  • Inadequate assessment to determine if opioids are clinically indicated. The Model Policy specifically states that prescribers “should use opioid therapy for chronic non-cancer pain only when safer and reasonably effective options have failed.”
  • Inadequate monitoring.
  • Lack of patient education and informed consent.
  • Dose escalation as a sole course of response to continued pain. The Model Policy specifically states that the prescriber should “maintain opioid dosage as low as possible and continue only if clear and objective outcomes are being met.”

The Model Policy then goes on to assure physicians that they will be considered to be using opioids legitimately (translation: will not be disciplined) if the investigation concludes that the use of opioids was for a legitimate medical purpose.

Indicia of legitimacy are:

  • Was there a valid physician-patient relationship?
  • Was the decision to use opioids based on sound clinical judgment and current best clinical practices, including consideration of alternatives?
  • Was the treatment with opioids appropriately documented?
  • Was the treatment with opioids appropriately monitored?
  • Was the treatment with opioids of demonstrable benefit to the patient?

A practice should have a firm policy in place as to when and how it will prescribe these drugs – these are not decisions that should be safely made ad hoc. This is even more critical if you do not practice pain management as your specialty and only occasionally prescribe opioids.

 

This policy should encompass several features:

 

1. Alternatives

 

Prescribing opioids for chronic non-cancer condition should typically not be a first choice. Removing a patient from dependence on these drugs should always be the goal. Having a clearly stated office policy on this issue- distributed to patients- can distinguish your practice from those that prescribe for profit or out of negligence.

 

Discussing alternatives to opioid use is also intrinsic to the Model Policy’s informed consent. This means a discussion of the risks and benefits of all options available to the patient, with a final settling on opioids as a shared decision.

 

2. A patient contract

A contract lists your office policies regarding appointments, prescriptions and patient conduct that the patient agrees to follow.

It will include the patient’s responsibility for safe medication use and storage and their consent to drug testing.

The contract will state grounds for termination from the practice, including lying about symptoms, lying about other medication sources, evidence of doctor-shopping as per the state’s prescription website (see below), stealing or dealing, refusal to be drug tested, or attempts to cheat when tested.

It is up to you to decide whether the penalty is immediate termination from the practice or a “strike” system. Whatever plan you use must be followed consistently between all patients.

3. Creating a proper record

The sine qua non of a pill mill is an office moving patients through with little actual attention.

Your records should reflect the opposite.

A documented medical history and complete physical examination must precede the first issuance of a prescription. Subsequent prescriptions should be generally not be written without a physician visit, including a note that addresses alternatives.

An evaluating board will be looking at whether you assessed the nature and intensity of the pain, past and current treatments for the pain, any underlying or co-occurring disorders – including mental illness and addiction – and the effect of the pain on the patient’s physical and psychological functioning .

Each visit should also document that you warned the patient about limitations on activities such as driving and operating machinery and that you reinforced warnings about safe storage if there are children or other vulnerable people in the home.

A copy of all patient instructions should be maintained in the patient’s chart.

In determining if you are maintaining your records defensibly bear in mind the statement in the Model Policy that “The Board will judge the validity of the physician’s treatment of a patient on the basis of available documentation, rather than solely on the quantity and duration of medication administered. The goal is the management of the patient’s pain while effectively addressing other aspects of the patient’s functioning, including physical, psychological, social and work-related factors, and mitigating risk of misuse, abuse, diversion and overdose.”

In other words, if you can justify a higher dose for a longer period you will be defensible. But prescribing a lower dose for a shorter interval without a solid record can be problematic.

4. The addicted patient

Patients who already have an active substance abuse problem should not receive opioid therapy until they are established in a treatment/recovery program or alternatives are established such as co-management with an addiction professional.

5. Monitoring

(i) For effectiveness

Opioid therapy should start as a test trial of the lowest reasonable dose for up to 90 days, with periodic evaluation points within it to assess the patient’s progress using the “5 A’s”: analgesia, activity improvements, adverse effects, aberrant behaviors attributable to the opioid and the affect of the patient

Once an effective dose is settled, evaluation should continue at monthly intervals.

(ii) For abuse

You must check your state’s prescription monitoring program, both to detect doctor-shopping and to avoid liability arising from drug interactions.

This should be done at regular intervals because an initially legitimate patient may not stay so.

If required by state law, you may report the patient to law enforcement as a permissible act under HIPAA. However, do not contact another prescribing physician directly to report the patient’s activities, as this is not a valid disclosure exception under HIPAA.

You may, however, contact another physician without the patient’s permission to request their records if YOU require such to treat your patient. This would most likely come up when you mistrust what the patient told you about prior treatment and that information impacts your current choices. This WILL come under the treatment exception in HIPAA. This is a point that an evaluating board would note in analyzing whether you properly assessed your patient before prescribing opioids.

You should also drug test all chronic non-cancer opioid patients on a regular basis, the universality and regularity also being protective against charges of discrimination. This will identify additional drugs the patient may be taking (but not disclosing). It will also reveal if the patient is actually taking what you prescribed (rather than selling it).

6. Pharmacy limits

Only one pharmacy should be designated. That pharmacy should also be informed to alert your office of inappropriate conduct by your patient on its premises, since that will be a violation of the patient contract and grounds for termination from your practice.

7. Replacement

Only one replacement, and only upon a verifiable loss or theft (the latter requiring a police report to have been filed), per patient should be your rule and the patient must be required to come to the office for the new prescription.

8. Termination

Terminating a patient for good cause does not relieve you from the requirement to avoid abandonment.

In addition to the usual requirement to cover emergency care (usually 30 days), you should offer appropriate referrals to addiction programs or specialists and should provide the patient with a one month’s prescription. It could be malpractice to force them into precipitous withdrawal.

II. Liability for undertreatment

With pain – of course actually a subjective issue – now oxymoronically deemed the “5th vital sign”, are you at risk for undertreating pain?

The answer – unsatisfyingly – is “maybe”.

Proper alleviation of a patient’s pain is part of your duty of care. It is therefore potentially actionable.

On the other hand, absent something further such as a suicide due to unremitting pain it is not easily separable as a damage from the patient’s underlying condition.

Therefore, to date there is no clear indication as to whether undertreatment will be a significant malpractice or professional discipline concern.

A 2001 California case (actually brought under an elder endangerment statute) noted that the undertreatment would have to be egregious, such as administering far too low a dose to be expected to be effective or providing oral medication to a patient who cannot easily swallow.

By contrast, your documentation of appropriate dosages as per clinical guidelines and evaluation for other causes of the pain should be adequate for defensibility. You just need to demonstrate you didn’t simply dispense opioids on a request. You treated the patient’s complaints as presumptively valid and worked with them to achieve the maximum analgesia safely possible.

Summary: State medical board policies emphasize the facts that opioids should not be a first resort and must be prescribed at the lowest level and for the shortest time that is effective. A reviewing body will look to the physician’s records for proof of the consideration of alternatives and the clinical justification for opioid treatment. It will also look for appropriate monitoring. A patient contract is essential and sanctions should be enforced. Addicted patients should be referred for treatment. Under-treatment is unlikely to be a source of liability.

[Medical Justice notes: The ultimate Goldilocks conundrum. Not too many opioids. Not too few opioids. The issue rears its head with chronic non-cancer pain. Boards of Medicine, Attorney Generals, and the DEA are focused on avoiding substandard treatment and diversion. The stakes are high. They go beyond just Board discipline. There are potential criminal penalties, including jail time. Don’t blame me. I’m just the messenger.

Chronic pain is best managed by those practitioners who have extensive experience – understanding the issues vis a vis addiction, diversion, and pain control. They also understand the paper trail required for proper compliance. We know several doctors who had a handful of difficult patients – and continued prescribing opioids over the years. When these patients were arrested for drug diversion or hospitalized for overdose, their problem became the doctor’s problem. None of these doctors were running pill mills. They just had a few difficult patients – and it was easier to provide higher and higher doses of opioids than refer them elsewhere.]

 

Are we are a country of FIFTY STATES… or 50 COLONIES of the Federal Government ?

https://www.nbcnews.com/storyline/legal-pot/sessions-end-obama-era-policy-legalized-marijuana-n834591

Attorney General Jeff Sessions is giving U.S. attorneys the green light to aggressively enforce federal laws against marijuana — even in states where pot is legal.

In doing so, Sessions is reversing an Obama administration policy that shielded legalized marijuana from federal intervention and enabled the pot industry to flourish, a senior Justice Department official told NBC News on Thursday.

Federal law prohibits growing, buying and using marijuana. And while Sessions is giving permission to prosecute marijuana cases, he did not explicitly call for it. One official in the Justice Department said the message is not that federal prosecutors should now go after the industry.

The move drew immediate condemnation from Colorado Sen. Cory Gardner, a Republican whose state legalized pot in 2014. He threatened to retaliate by holding up confirmation of Sessions’ picks for top DOJ positions.

The previous Justice Department policy, which was laid out in a 2013 memo from the deputy attorney general at the time, James Cole, said federal prosecutions would focus on cases of peddling pot to minors, selling marijuana across state borders or growing pot on federal land, or when it involved gangs or organized crime.

A senior Justice Department official said one reason for the change is that the previous policy “was perceived to have created a safe harbor for the industry to operate.”

The move by the nation’s top law enforcement official comes the same week that California began selling recreational marijuana.

Image: US-POLITICS-TRUMP-TAX-REFORM

Attorney General Jeff Sessions at the White House on Dec. 20. Brendan Smialowski / AFP – Getty Images

It is also legal in Alaska, Maine, Massachusetts, Nevada, Oregon and Washington. There are also thriving medical marijuana programs in 28 states.

The head of the Drug Policy Alliance said Sessions is defying the 64 percent of the American people who support marijuana legalization.

“Jeff Sessions’ obsession with marijuana prohibition defies logic, threatens successful state-level reforms, and flies in the face of widespread public support for legalization,” said executive director Maria McFarland Sánchez-Moreno. “It’s now time for Congress to put the brakes on Sessions’ destructive agenda by limiting the Justice Department’s ability to undermine states’ decision-making.”

Related: Opinion: Sessions is on the wrong side of marijuana legalization

Sessions has just shown “how out of touch he is with scientists and taxpayers” and that siccing federal prosecutors on pot offenders will just needlessly jam the jails with more prisoners, said Jasmine Taylor of Human Rights Watch.

“This will no doubt spike arrests and fuel mass incarceration, largely for people of color, but this administration has been clear from their campaign promises of harsh policies that trample rights that this day would eventually come to pass,” Taylor said. “The war on drugs, whether it went away or just slowed down, is now back.”

Amy Margolis of Greenspoon Marder, which has a cannabis practice, warned Sessions’ order “sets up a serious potential battle between the states with legalization and United States attorneys who decide to enforce federal law against the will of the voters and, in some cases, state legislatures.”

“This battle will, unfortunately, play out in the courts while businesses or individuals are facing criminal charges for engaging in conduct that is legal in their state,” Margolis said in an email to NBC News. “And, in large states, like California, federal law could be applied differently in different districts resulting in patchwork prosecutions even within state lines.”

Anti-marijuana activist Kevin Sabet praised Sessions’ order, calling it “a good day for public health.”

“The days of safe harbor for multi-million dollar pot investments are over,” said Sabet, a former Obama Administration drug policy adviser who now heads Smart Approaches to Marijuana (SAM). “DOJ’s move will slow down the rise of Big Marijuana and stop the massive infusion of money going to fund pot candies, cookies, ice creams, and other kid-friendly pot edibles. Investor, banker, funder beware.”

Sessions has long been a cannabis foe who famously said “good people don’t smoke marijuana” during a 2016 Senate hearing. He also was accused of telling late assistant U.S. Attorney Thomas Figures that he thought the KKK was “OK until I found out they smoked pot.”

This was after Sessions learned that Klan members had gotten high the night they kidnapped and murdered a young black man. Sessions insisted he was joking.

Pharmacists: reluctance to treat drug-addicted people ?

Pharmacists Slow to Dispense Lifesaving Overdose Drug

https://www.medscape.com/viewarticle/890852

Gale Dunham, a pharmacist in Calistoga, Calif., knows the devastation the opioid epidemic has wrought, and she is glad the anti-overdose drug naloxone is becoming more accessible.

But so far, Dunham said, she has not taken advantage of a California law that allows pharmacists to dispense the medication to patients without a doctor’s prescription. She said she plans to take the training required at some point but has not yet seen much demand for the drug.

“I don’t think people who are heroin addicts or taking a lot of opioids think that they need it,” Dunham said. “Here, nobody comes and asks for it.”

In the three years since the California law took effect, pharmacists have been slow to dispense naloxone, which reverses the effects of an overdose. They cite several reasons, including low public awareness, heavy workloads, fear that they won’t be adequately paid and reluctance to treat drug-addicted people.

 

In 48 states and Washington, D.C., pharmacists have flexibility in supplying the drug without a prescription to patients, or to their friends or relatives, according to the National Alliance of State Pharmacy Associations. But as in California, pharmacists in many states, including Wisconsin and Kentucky, have divergent opinions about whether to dispense naloxone.

“The fact that we don’t have wider uptake … is a public health emergency in and of itself,” said Virginia Herold, executive officer of the California State Board of Pharmacy. She said both pharmacists and the public need to be better educated about the drug.

Pharmacists are uniquely positioned to identify those at risk and help save the lives of patients who overdose on opioids, said Talia Puzantian, a pharmacist and associate professor of clinical sciences at Keck Graduate Institute School of Pharmacy in Claremont, Calif.

“There’s a Starbucks on every corner. What else is on every corner? A pharmacy. So we are very accessible,” Puzantian told a group of pharmacy students recently as she trained them on providing naloxone to customers. “We are interfacing with patients who may be at risk. We can help reduce overdose deaths by expanding access to naloxone.”

Opioid overdoses killed 2,000 people in California and 15,000 nationwide in 2015.

Naloxone can be administered via nasal spray, injection or auto-injector. Prices for it vary widely, but insurers often cover it. The drug binds to opioid receptors, reversing the effect of opioids and helping someone who has overdosed to breathe again.

At least 26,500 overdoses were reversed from 1996 to 2014 because of naloxone administered by laypeople, according to the National Institute on Drug Abuse. Since then, the drug has become much more widely available among first responders, law enforcement officers and community groups. The drug is safe and doesn’t have serious side effects, apart from putting someone into immediate withdrawal, according to the institute.

Information on how many pharmacists are dispensing naloxone is limited, but one study last year showed access to the drug at retail pharmacies increased significantly from 2013 to 2015 from previously small numbers.

 

Interviews and available evidence from around the U.S. indicate that pharmacists have varying perspectives. In Kentucky, for example, one study found that 28 percent of pharmacists surveyed were not willing to dispense naloxone.

 

In Pennsylvania, pharmacists weren’t exactly lining up to hand out naloxone when the state passed a law in 2015 allowing them to do it, said Pat Epple, CEO of the Pennsylvania Pharmacists Association. She said there were some initial obstacles, including the cost of the drug and pharmacists’ limited awareness of the law. The association worked with state health officials to raise awareness of naloxone among patients and pharmacists and reduce the stigma of dispensing it, Epple said.

 

Wisconsin is also among the states that allow pharmacists to dispense naloxone. Sarah Sorum, a vice president at the Pharmacy Society of Wisconsin, said the state’s pharmacists want to expand their public health role and help curb the opioid epidemic. But reimbursement has been a challenge, she said.

 

Not all health plans across the nation cover the full cost of the drug, and pharmacists also are concerned about getting paid for the time it takes to counsel patients or their relatives.

 

California and other states require pharmacists to undergo training before they can dispense naloxone to patients who don’t have a doctor’s prescription. Puzantian and others say that in California not enough pharmacists are getting the training, which can be taken online or in person and can cost a few hundred dollars.

 

So far, the California State Board of Pharmacy has trained between 450 and 500 pharmacists, and the membership-based California Pharmacists Association has added an additional 170. Other smaller organizations offer the naloxone training, according to the association. There are about 28,000 licensed pharmacists in the state.

 

Once trained, California pharmacists who provide naloxone must screen patients to find out if they have a history of opioid use. They also must counsel people requesting the drug on how to prevent, recognize and respond to an overdose.

 

Some say training requirements are an unnecessary barrier, especially given the high level of education already required to become a pharmacist.

 

Some of the bigger pharmacy chains, including CVS, Rite Aid and Walgreens, have made the drug available without a prescription in the states that allow it. Walgreens has announced that it would stock the nasal spray version of naloxone at all of its pharmacies. It said it offers the drug in 45 states without requiring the patient to have a prescription.

 

Peter Lurie, president of the Center for Science in the Public Interest, said not every pharmacy has to dispense naloxone for people to have access to it. “But the greater the number of dispensing pharmacies the better,” he said, adding that it is “especially important in more sparsely populated areas.”

 

Corey Davis, deputy director of the Network for Public Health Law, said making naloxone available over the counter would also increase access, since people could buy it off the shelf without talking to a pharmacist.

 

Bryan Koschak, a community pharmacist at Shopko in Redding, Calif., said people should go to a hospital or doctor’s office for naloxone. “I am not champing at the bit to do it,” he said. “It is one more thing on my plate that I would have to do.”

 

Michael Creason, a pharmacist in San Diego expressed a different view. He did the training after his employer, CVS, required it. He said pharmacies are a great vehicle for expanding access to naloxone because patients often develop a rapport with their pharmacists and feel comfortable asking for it.

 

Pharmacy associations should educate their members about the laws that allow naloxone to be provided without a doctor’s prescription and persuade more of them to provide the drug to customers who need it, Lurie said. Others say more pharmacists should put up signs to make customers aware that naloxone is available in their shops.

 

The California Pharmacists Association said it is trying to raise awareness through newsletters and emails to pharmacists in the state. “We want to see every pharmacy be able to furnish naloxone and every person at risk have access to it,” said Jon Roth, the association’s CEO.

 

The state’s pharmacy schools also include the training in their curriculum. One day recently, Puzantian explained to a classroom full of pharmacy students that naloxone is effective, safe and can prevent death.

 

“You can’t get a dead addict into recovery,” she told the students. Drug users “might have multiple overdoses, but each overdose reversal is a chance for them to get into recovery.”

“opiophobic Idiotiana “… now going after rehab clinics in Idiotianapolis surburb ?

Lawsuit by Doctors in Indiana Against DEA agents and the City

www.doctorsofcourage.org/lawsuit-by-doctors-in-indiana-against-dea-agents-and-the-city/

Four doctors in Carmel, IN, a suburb of Indianapolis, have sued the city and government officials responsible for the illegal attack on their clinic, Drug Opiate & Recovery Network (DORN), an addiction center prescribing Suboxone, in July, 2014.  The lawsuit asks for compensatory and punitive damages and requests a jury trial. Drs. Larry Ley, founder, George Agapios, Ronald Vierk, and Luella Bangura were all arrested and charged, in spite of years of continuous communication with DEA officials.  This shows the evil in the DEA.

“They destroyed the lives of 12 people that were actively trying to fight this disease, and they threw all the patients who were actively fighting addiction to the curb,” said Dr. Ley. In spite of the charges being dropped against them, or the acquittal of Dr. Ley, shedding the stigma of the raid has proved difficult for the clinic’s doctors and staff since the arrests, which is why they decided to take legal action. The employees have been unable to find other work, even though their records have been expunged.

The attorneys for the city and some of the officials have declared immunity in the lawsuit. That is the protective umbrella by which these unscrupulous DOJ officials are carrying out illegal attacks against legitimate practitioners across the country, and something we, the citizens, must remove. If a government official knowingly attacks an innocent citizen for illegal purposes, that official should be held accountable. If not, this country is moving into a police state. The plaintiffs’ claims of false imprisonment and arrest are also possibly barred due to a probable cause being filed in the case, even though that probable cause was created through perjury. Also, to show how the DOJ colludes in their illegal attacks on doctors, Assistant U.S. Attorney Josh Minkler who was first offended by the behavior of DEA agent Gary Whisenand pushing the case against Dr. Ley, is now representing Whisenand in the civil suit.

The new complaint of false arrest and violating their right to due process is against DEA agent Whisenand, the city of Carmel and Major Aaron Dietz of the Hamilton/Boone County Drug Task Force. But Dietz’s attorneys claim he was acting in good faith and is therefore immune from civil action under law. Good faith—Bull shit!! The target was picked, the case was created.

In the government’s standard propagandizing media collusion when doctors are attacked, Dietz was quoted as saying

“We make no distinction between Dr. Ley and any other drug dealer,” calling the clinic a “pill mill” and Dr. Ley “the Pablo Escobar of Suboxone.” “This type of ruse of a clinic perpetuates the problem.  Those people are still addicted to the drug and this is what’s happening.  This is not fixing the problem,” “Opiate drugs and prescription medication is a gateway to heroin.  That’s why we have heroin is because people get addicted to the opiate drug prescription medication and then go to a cheaper, readily available heroin.”

Now all of those statements are lies stated in public to defame a proper, law-abiding citizen. Shouldn’t that perpetrator of illegal activity (Dietz) have to pay for his crimes?

Dietz and Whisenand worked for months to create a case against the doctors. This is an example of tax dollars being wasted. They spent nine months watching hundreds of patients comes and go from the clinics, compiling more than 26,000 hours of video surveillance in the process. But they were unable to identify a single individual who was paying for a drug they didn’t legitimately need. So they invented some by sending undercover officers to lie about being dependent on opiates. So probable cause was a creation of the government.

Then, despite being told twice by the U.S. attorney’s office that they didn’t have a case against Ley, they arrested Ley and 11 of his employees for “providing Suboxone prescriptions to the undercover officers who had no legitimate medical need for them.”

This is a standard practice in all attacks on doctors, and primarily what they are being convicted of: “illegitimate medical practice” because the DEA agents lie to get drugs prescribed that they don’t really need. Who’s committing the crime here? But as the suspected “ringleader” of the operation Ley was booked on $1 million bond, his assets seized, and he spent a month in jail.

One by one the cases against Ley’s 11 co-defendants fell apart, as prosecutors failed to provide enough evidence that a crime had been committed. Dr. Ley was the only DORN defendant to go to trial. The charges against him applied to just 22 prescriptions for Suboxone—all written to police officers pretending to legitimately need them. That fact was not lost on Hamilton County Judge Steven R. Nation, presiding over Ley’s trial.

“I struggled with this case the minute I started to watch the surveillance videos [of the undercover agents],” Nation said, prior to announcing Ley’s acquittal. “I’ve got conditions that people were asking to be treated for [and] the drug that was issued was appropriate for what they were being asked to be treated for.”

Why aren’t more judges seeing this fact? Maybe because they ride the gravy train of convictions too?  Judges are not unbiased in these cases where money is funneled into the Department of Justice and their own courts. Ethics and morals are found less and less in the legal profession.  But at least in this case under this judge, Ley was cleared of all charges after an eight-day bench trial and all other charges against him in other counties where he ran clinics were dropped.

Jim Crum, Dr. Ley’s defense attorney stated what every defense across the country should be stating:

“Our position has been, and the judge agreed, that the judges point that if there was a violation of anything here it’s a licensing issue.” Is the doctor following the rules exactly? “Even if he wasn’t that doesn’t rise to the level of a criminal offense. There was no intent to deal, everything was in the confines of the normal practice of medicine.”

James Brainard, Mayor of Carmel

Dr. Ley was acquitted in August 2016, two years after the raid. Similar clinics across the country are being attacked and the doctors incarcerated. But here, the reason is obvious—a politically motivated effort to help developers in Carmel, directed by Mayor James Brainard. I won’t go into the possible collusion between Mayor Brainard, the Carmel Redevelopment Commission, and Pedcor here. But a detailed review of public records showed that the city had its eye on the property before Dr. Ley became a subject of a criminal investigation. In 2016, just months before the start of Ley’s trial, the city of Carmel revealed a takeover of the property across the street and construct a new mixed-use development called the “PNC Block Redevelopment” involving condominiums, commercial office space, underground parking, and an outdoor beer garden. If the goal was to force Ley out of Carmel, a conviction wasn’t necessary. DORN’s main office in Carmel never reopened, and Ley sold it for a loss to a real-estate investor.

So what is the result of attacks on legitimate clinics like this on the occurrence of addiction? Use Indiana as an example. Thanks in part to the policies of former Indiana Governor Mike Pence, treatment options in Indiana were limited even before Dr. Ley’s arrest. The state ranked 47th out of 50 states for availability of drug and alcohol treatment and Suboxone treatment was among the worst in the nation. Hamilton County ranked ninth out of 92 counties for heroin overdoses. In Indianapolis drug overdose fatalities increased seven-fold since 2000. Hamilton County alone has seen a 45 percent increase in heroin-related deaths. In 2015 more than 300 non-fatal overdoses were recorded in the four counties where Ley practiced. Two years after the closure of the DORN clinic, fatal overdoses in Indiana have risen by double digits, with only three providers certified to prescribe Suboxone in the entire city of Carmel.